Pfizer Acquires Alacer; FDA Grants Repros Therapeutics Meeting for Androxal® Print E-mail
By Staff and Wire Reports   
Monday, 27 February 2012 19:37
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 27, 2012.

Pfizer Inc. (NYSE:PFE)
announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.

Based in Foothill Ranch, California, Alacer is well-known among health-conscious consumers as a provider of Vitamin C supplement products. It produces almost 500 million packets of Emergen-C annually, and its products are sold in health food stores, supermarkets, drug stores, mass merchandisers and club stores nationwide.

“We are very pleased that the Emergen-C family of products will become part of Pfizer’s portfolio. We expect that our global network and deep expertise in dietary supplements combined with our desire to provide consumers with high-quality products will make Emergen-C more accessible than it has ever been before,” said Paul Sturman, President of Pfizer Consumer Healthcare. “Emergen-C products add to and greatly complement our market-leading dietary supplement portfolio.”

Emergen-C is an effervescent, powdered drink mix vitamin supplement that supports active and healthy lifestyles. Available in more than 15 flavors, each of the seven lines of Emergen-C is packed with nutrients, Vitamins C and B, electrolytes and antioxidants. Specialty formulations include Emergen-C Kidz® designed specifically for children, and specialty formulas that support specific health needs such as joint health and heart health.


Repros Therapeutics Inc.® (Nasdaq: RPRX)
announced the FDA has granted a meeting with the Company to discuss the design of pivotal Phase 3 efficacy studies for Androxal®, as well as the components of the overall drug development program required for NDA submission. The meeting has been scheduled for the first half of May, 2012.

Androxal® is an oral therapy intended for the treatment of secondary hypogonadism. Androxal® treats the underlying mechanism that the Company believes results in the majority of the cases of secondary hypogonadism.

Also Monday:

Access Plans, Inc. (OTCBB: APNC)
, a marketing company specializing in turnkey, private-label membership benefit plans that provide discount products and services, protection benefits and retail services to more than one million customers in the United States and Canada, announced today that it has entered into a definitive agreement to be acquired by Aon Affinity.

Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced that Ron Cohen, M.D., President & CEO, will present at the Cowen & Company 32nd Annual Health Care Conference on Monday, March 5, 2012 at 4:50 pm ET at the Boston Marriott Copley Place, Boston, Massachusetts.

Advaxis, Inc., (OTCBB: ADXS)
, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed the first of 3 dose cohorts in the single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV in the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

Affymax, Inc. (Nasdaq: AFFY)
today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Cowen and Company 32nd Annual Health Care Conference in Boston at 1:30 p.m. Eastern time on Monday, March 5, 2012.

Alkermes plc (NASDAQ: ALKS)
announced today that its corporate presentation will be webcast live at the Cowen & Company 32nd Annual Health Care Conference on Monday, March 5, 2012, at 3:30 p.m. EST (8:30 p.m. GMT) from the Boston Marriott Copley Place.

Antares Pharma, Inc. (NYSE Amex: AIS)
today announced the appointment of John “Jack” Howarth as Vice President of Corporate Affairs.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
today announced that it will webcast its presentation at the Cowen and Company 32nd Annual Health Care Conference in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, March 6, 2012 at 9:20 a.m. (ET).

Array BioPharma Inc. (Nasdaq: ARRY)
today announced that its President and Chief Scientific Officer, Kevin Koch, Ph.D., will speak at the Cowen and Company 32nd Annual Health Care Conference in Boston.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference on Monday, March 5, 2012 at 4:10 p.m. (EST) in Boston.

, announced today that it has closed its previously announced $15 million private placement to healthcare-focused U.S. institutional investors.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
today announced presentation of results from a Phase Ib clinical study that show its GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma (PDA), from 3.3 months when treated with ipilimumab (IPI; Yervoy; BMS), to 5.5 months on the combination of IPI plus GVAX Pancreas, an increase of more than 60 percent.

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI)
, a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

Celsius Holdings, Inc. (PINKSHEETS: CELH)
, the creator and marketer of Celsius®, Your Ultimate Fitness Partner®, today reported their results of operations for the fourth quarter and year ended December 31, 2011.

Speaking today at the Targets and Strategies in Drug Discovery Summit in Las Vegas, Dr. Gady Cojocaru, Head of Target Discovery at Compugen Ltd. (NASDAQ: CGEN), presented Compugen’s prediction based discovery strategy by focusing on two of the methodologies being utilized by the Company for the identification of novel targets for monoclonal antibody (mAb) cancer therapy.

CytRx Corporation (Nasdaq: CYTR)
, a biopharmaceutical company specializing in oncology, today announced that Vice President of Business Development David J. Haen will present at the Cowen & Company 32nd Annual Health Care Conference on Monday, March 5, at 4:10 p.m. Eastern time (1:10 p.m. Pacific time).

Dendreon Corporation (Nasdaq: DNDN)
today reported results for the year and quarter ended December 31, 2011.

Greyson International, Inc. (GYSN.PK)
announced today that it has purchased, for investment, a private entity which has a significant interest in an oil and gas company. The acquisition is subject to final terms and conditions.

today announced that the National Governors Association (NGA) presented HP Enterprise Services with the 6th Annual Public-Private Partnership Award at its annual meeting in Washington, D.C., on Saturday.

Human Genome Sciences, Inc. (Nasdaq: HGSI)
today announced financial results for the quarter and full year ended December 31, 2011, and provided highlights of recent key developments.

iCAD, Inc. (Nasdaq: ICAD)
, an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2011.

Idera Pharmaceuticals (Nasdaq: IDRA)
today announced that Nicola La Monica, Ph.D., Vice President of Biology at Idera, will present at the Cancer Immunotherapy Summit on February 28, 2012, at 2:30 pm ET in Boston, MA.

Illumina, Inc. (NASDAQ: ILMN)
, a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today issued the following statement regarding Roche’s decision to extend its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
will host a conference call on Tuesday, March 13, 2012, at 4:30 p.m. ET.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
will present at the Cowen and Company 32nd Annual Health Care Conference on Monday, March 5, 2012 at 4:10 p.m. Eastern Time at the Marriott Copley Place in Boston.

Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), recently completed the manufacture of a human rhinovirus Type 16 challenge stock.

Meridian Bioscience, Inc. (NASDAQ: VIVO)
today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella™, a new rapid assay for detection of legionellosis.

MMRGlobal, Inc. (OTCBB: MMRF)
("MMR"), a leading provider of Personal Health Records (PHRs) and electronic document management and imaging systems for healthcare professionals, today announced that as a result of overwhelming reaction to the Company's prepaid PHR card by retailers, hospitals administrators, physicians, home care agencies, assisted living facilities, home health suppliers, supermarkets and Chief Technology Officers of EMR providers, MMR plans on manufacturing and distributing more than 500,000 cards in 2012 at a suggested retail price of $99.95 for the first year.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB)
a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, March 1, 2012 to provide a business update and discuss its fourth-quarter and full-year 2011 financial and operational results.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, is joining the National Organization for Rare Disorders (NORD) and other organizations around the world today to observe World Rare Disease Day on February 29, 2012.

Opexa Therapeutics, Inc. (NASDAQ:OPXA)
, a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

Pfizer Inc. (NYSE:PFE)
today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that Michael J. Culotta, Executive Vice President and Chief Financial Officer, will make a presentation regarding the Company at RBC Capital Markets’ 2012 Healthcare Conference in New York City, on Wednesday, February 29, 2012, at 10:30 a.m. Eastern Time.

In an exclusive video interview with BioMedReports', Richard T. Schumacher, the founder and Chief Executive Officer of Pressure BioSciences Inc. (NASDAQ: PBIO), tells investors about his firm, their science and the building momentum that has seen interest and volume in the stock rising in recent months.

Polycom, Inc. (NASDAQ: PLCM)
, the global leader in standards-based unified communications (UC), today unveiled Polycom® RealPresence® Mobile for smartphones, available in early March on the Apple iPhone 4S and soon on Android 4.0 (Ice Cream Sandwich) smartphones.

Repligen Corporation (NASDAQ:RGEN)
today announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the manufacture of biopharmaceuticals.

announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN), at a price of $44.50 per share, to 6:00 p.m., New York City time, on March 23, 2012.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
today announced financial and operating results for the fourth quarter and full year ended December 31, 2011 and other business updates.

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter and full year 2011 financial results after market close on Monday, March 5, 2012.

Senomyx, Inc. (NASDAQ: SNMX) will release its financial results for the fourth quarter and fiscal year ended December 31, 2011 on Thursday, March 1, 2012 before the opening of the U.S. financial markets.

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
, a specialty pharmaceutical company, today announced that it will release its full year and fourth quarter 2011 financial results on Thursday, March 8, 2012 after the close of the U.S. financial markets.

St. Jude Medical, Inc. (NYSE:STJ)
, a global medical device company, today announced that its Board of Directors declared a 10 percent increase in the company’s quarterly dividend to $0.23 per common share.

VentriPoint Diagnostics (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) announces it has completed the validation test, which compared the VentriPoint Medical System (VMS™) to cardiac Magnetic Resonance Imaging (MRI) in patients with Pulmonary Arterial Hypertension (PAH).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus